Clinical Trial Update: Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of docetaxel, cisplatin, and capecitabine (DCX) for nasopharyngeal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Neoplasms | Phase 2 | Status: COMPLETED